Humacyte, Inc. (HUMA) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to Humacyte fourth quarter and full year 2025 earnings conference call. Currently, all participants are in a listen-only mode. Later, we will conduct a question and answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded. I will now turn the call over to Tom Johnson with LifeSite Advisors. Please go ahead. Thank you, Operator. Before we proceed with the call, I'd like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made in this call is contained in our periodic reports filed with the SEC. Forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise these forward-looking statements except as required by law. Information presented on this call is contained in the press releases issued this morning and in our Form 10-K, which after filing may be accessed from the investor page of the HumaCite website. Joining me on today's call from HumaCite are Dr. Laura Nicholson, President and Chief Executive Officer, and Dale Sander, Chief Financial Officer. and Chief Development Officer. Dr. Nicholson will provide a summary of the company's progress for the fourth quarter and in recent weeks, and Dale will review the financial results for the quarter and year end of December 31, 2025. I will now turn the call over to Dr. Nicholson. Laura? Thank you, Tom. Good mor...